Literature DB >> 7539936

Natural protection against HIV-1 infection provided by HIV-2.

K Travers1, S Mboup, R Marlink, A Guèye-Nidaye, T Siby, I Thior, I Traore, A Dieng-Sarr, J L Sankalé, C Mullins.   

Abstract

Significant differences have been observed in the rates of transmission and disease development in human immunodeficiency virus (HIV) types 1 and 2. Because many HIV-2-infected people remain asymptomatic for prolonged periods, the hypothesis that HIV-2 might protect against subsequent infection by HIV-1 was considered. During a 9-year period in Dakar, Senegal, the seroincidence of both HIV types was measured in a cohort of commercial sex workers. Despite a higher incidence of other sexually transmitted diseases (STDs), HIV-2-infected women had a lower incidence of HIV-1 than did HIV-seronegative women, with a relative risk of 0.32 (P = 0.008). An understanding of the cross-protective mechanisms involved may be directly relevant to HIV-1 vaccine development.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539936     DOI: 10.1126/science.7539936

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  32 in total

Review 1.  Current concepts in human immunodeficiency virus infection and AIDS.

Authors:  S A Schwartz; M P Nair
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Human immunodeficiency virus type 2 envelope glycoprotein binds to CD8 as well as to CD4 molecules on human T cells.

Authors:  H Kaneko; L P Neoh; N Takeda; H Akimoto; T Hishikawa; H Hashimoto; S Hirose; S Karaki; M Takiguchi; H Nakauchi; Y Kaneko; N Yamamoto; I Sekigawa
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  The sequence and structure of the 3' arm of the first stem-loop of the human immunodeficiency virus type 2 trans-activation responsive region mediate Tat-2 transactivation.

Authors:  C Browning; J M Hilfinger; S Rainier; V Lin; S Hedderwick; M Smith; D M Markovitz
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 4.  Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1).

Authors:  B J Doranz; J F Berson; J Rucker; R W Doms
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

Review 5.  Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm?

Authors:  W C Koff; A M Schultz
Journal:  J Clin Immunol       Date:  1996-05       Impact factor: 8.317

Review 6.  A potentially novel approach for the gene therapy of HIV-1 disease.

Authors:  Z N Berneman
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

7.  Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.

Authors:  C J Miller; M B McChesney; X Lü; P J Dailey; C Chutkowski; D Lu; P Brosio; B Roberts; Y Lu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 8.  Coinfecting viruses as determinants of HIV disease.

Authors:  Andrea Lisco; Christophe Vanpouille; Leonid Margolis
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

9.  Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain.

Authors:  G D Ritter; G Yamshchikov; S J Cohen; M J Mulligan
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Multivariate statistical analyses demonstrate unique host immune responses to single and dual lentiviral infection.

Authors:  Sunando Roy; Jennie Lavine; Francesca Chiaromonte; Julie Terwee; Sue VandeWoude; Ottar Bjornstad; Mary Poss
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.